OmniAb, Inc.
Christine Vuong has a strong background in research and vaccine development in the field of immunology. Christine is currently working as a Senior Research Scientist at OmniAb, Inc. since September 2022. Prior to this, they worked as a Research Scientist at Ligand Pharmaceuticals from September 2021 to September 2022.
Christine gained extensive experience during their time at the University of Arkansas, where they served as a Research Scientist from January 2019 to October 2021. In this role, they were involved in the development of poultry vaccines, immunoassays, and feed supplements to treat heat stress, disease susceptibility, and gut inflammation. Christine successfully obtained over $1 million in research funding. Additionally, they worked as a Post-Doctoral Associate at the university from January 2018 to January 2019, focusing on projects related to the development and production of inclusion body hepatitis and Histomonas vaccines.
Prior to their work at the University of Arkansas, Christine worked at Texas A&M University. Christine served as a Graduate Research Assistant from October 2012 to December 2017, specializing in immunology. Their primary projects included monoclonal antibody production, isolation and characterization of chicken APCs, and immunoassay and diagnostics development. Christine also worked as a Graduate Teaching Assistant, providing instruction and course assistance in experimental immunology and vaccinology. Earlier in their career, they worked as a Graduate Research Assistant in virology from June 2010 to October 2012, focusing on projects related to avian influenza vaccines, Newcastle Disease Virus genotyping, and avian virus screening in bobwhite quail.
Overall, Christine Vuong has a diverse range of research experience and expertise in immunology, vaccine development, and poultry health, with a successful track record in securing research funding.
Christine Vuong's education history includes attending Texas A&M University, although the specific dates and degree obtained are not mentioned. Additionally, from 2018 to 2019, they pursued a post-doctoral associate position in Vaccine Development at the University of Arkansas. The field of study for both educational experiences is not specified.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.